PDF DatasheetHuman Anti-CD45 / LCA Antibody Product Attributes
CD45 / LCA Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD45 / LCA antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. More moderate antibody staining intensity was present in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. Low, but measureable presence of CD45 / LCA could be seen in. We were unable to detect CD45 / LCA in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD45 / LCA expression as measured by anti-CD45 / LCA antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | +++ | – | – | – | – | – | – | – | – | – | – |
| PTPRC Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| CD45 / LCA General Information | |
|---|---|
| Alternate Names | |
| Protein tyrosine phosphatase, receptor type, C, PTPRC | |
| Molecular Weight | |
| 180-220kDa | |
| Chromosomal Location | |
| 1q31.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | PTPRC |
| Entrez Gene ID | 5788 |
| Ensemble Gene ID | ENSG00000081237, ENSG00000262418 |
| RefSeq Protein Accession(s) | XP_006711537, XP_006711536, XP_006711535, NP_563578, NP_001254727, NP_002829 |
| RefSeq mRNA Accession(s) | XM_006711473, XM_006711474, NM_080921, NM_080922, NM_001267798, NM_002838, XM_006711472, NR_052021 |
| RefSeq Genomic Accession(s) | NG_007730, NC_000001, NW_003315907, NC_018912 |
| UniProt ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| UniGene ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| HGNC ID(s) | 9666 |
| Cosmic ID(s) | PTPRC |
| KEGG Gene ID(s) | hsa:5788 |
| PharmGKB ID(s) | PA34011 |
| General Description of CD45 / LCA. | |
| CD45R, also designated CD45, PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5,, 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6), CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45R functions as a phosphor-tyrosine phosphatase. This MAb reacts with all isoforms of CD45R expressed by all hematopoietic cells, except erythrocytes, having a higher level of expression on lymphocytes than on granulocytes (Workshop IV). Antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms. | |
Zoey Niu
I have tried a ton of CD45 primary antibodies and finally decided this one. For me, it recognizes CD45 on leucocytes in the bloodstream. The picture shows a spike experiment (cancer cell into healthy blood), CK in Cy3, CD45 shows up in green. I have two other isotypes in the panel for multi-color staining: mouse IgG2a and mouse IgG1. They do not cross-react if use the correct secondary.